In this article, we are going to look at the 5 Best Aggressive Growth Stocks to Buy According to Wall Street Analysts. For a longer list and more details on how we picked these stocks, you can go to 10 Best Aggressive Growth Stocks to Buy According to Wall Street Analysts.

5. Reddit, Inc. (NYSE:RDDT)

Year-Over-Year Revenue Growth: 70.64%

Average Price Target Upside Potential According to Analysts: 45.76%

Number of Hedge Fund Holders: 82

Reddit, Inc. (NYSE:RDDT) is one of the best aggressive growth stocks to buy according to Wall Street analysts. On May 6, Phillip Securities downgraded its rating on Reddit, Inc. (NYSE:RDDT) from Buy to Accumulate and reduced its price target from $240 to $200.

The company reported Q1 2026 results that were below the firm’s estimates. Reddit, Inc. (NYSE:RDDT) reported revenue of $663 million, up 69% year-over-year. Net income increased 680% to $204 million, while the company’s gross margin improved to 91.5% from 90.5% in the same period last year. Reddit, Inc.’s (NYSE:RDDT) growth was mainly driven by the advertising segment, which benefited from gains in both impressions and pricing.

However, Phillip Securities lowered its fiscal 2026 revenue forecast by about 10% and cut its net income estimate by 2%. The research firm noted that Reddit, Inc. (NYSE:RDDT) is moving toward more normal advertising growth after initial gains seen post-IPO.

The firm added that momentum could continue to be driven by the expansion of the Reddit Max AI ad suite, steady growth in average revenue per user, and high-margin data-licensing deals.

Reddit, Inc. (NYSE:RDDT) operates as a social media platform that allows registered users to submit content to the site, which is one of the most visited websites in the world.

4. Palantir Technologies Inc. (NASDAQ:PLTR)

Year-Over-Year Revenue Growth: 67.71%

Average Price Target Upside Potential According to Analysts: 46.10%

Number of Hedge Fund Holders: 89

Palantir Technologies Inc. (NASDAQ:PLTR) is one of the best aggressive growth stocks to buy according to Wall Street analysts. On May 11, Freedom Broker lifted its price target on Palantir Technologies Inc. (NASDAQ:PLTR) from $170 to $230 while keeping a Buy rating on the stock.

The research firm pointed to the company’s Q1 2026 results, which surpassed guidance and analyst estimates. The main driver was the US government segment, which saw unprecedented demand for national security solutions. This high demand created a shortage in implementation capacity.

Due to this pressure, Palantir Technologies Inc. (NASDAQ:PLTR) had to strictly prioritize defense contracts over commercial deals. In response to the demand, management also significantly lifted its fiscal 2026 guidance across key metrics.

Freedom Broker updated its financial model and materially raised its estimates for revenue and adjusted free cash flow from 2026 through 2028. The research firm pointed out that even though competition for top AI talent is growing, Palantir Technologies Inc. (NASDAQ:PLTR) still has a unique structural advantage.

Palantir Technologies Inc. (NASDAQ:PLTR) is an American software company that specializes in big data analytics and AI platforms. The company serves key government and commercial enterprises.

3. Amphenol Corporation (NYSE:APH)

Year-Over-Year Revenue Growth: 54.40%

Average Price Target Upside Potential According to Analysts: 46.97%

Number of Hedge Fund Holders: 103

Amphenol Corporation (NYSE:APH) is one of the best aggressive growth stocks to buy according to Wall Street analysts. On May 1, Seaport Research increased its price target on Amphenol Corporation (NYSE:APH) from $210 to $215 and maintained its Buy rating on the stock.

This update comes after the company reported strong Q1 2026 results. Seaport Research said that it raised its price target on Amphenol Corporation (NYSE:APH) because of strong organic sales growth, a strong book-to-bill ratio, and a healthy pipeline of acquisitions.

Earlier, on April 30, JPMorgan also increased its price target on Amphenol Corporation (NYSE:APH) from $190 to $200 and maintained an Overweight rating on the stock after the company reported Q1 2026 results.

The research firm pointed out that Amphenol Corporation (NYSE:APH) is “back to its typical trajectory of material beats and raises.” Additionally, JPMorgan pointed to the company’s “robust exposure to AI tailwinds combined with best-in-class execution” for the increase in the price target.

Amphenol Corporation (NYSE:APH) is a leading global company that specializes in the design, manufacturing, and marketing of electrical, electronic and fiber optic connectors and interconnect systems, antennas, sensors and sensor-based products, and coaxial and high-speed specialty cable.

2. MercadoLibre, Inc. (NASDAQ:MELI)

Year-Over-Year Revenue Growth: 42.11%

Average Price Target Upside Potential According to Analysts: 54.11%

Number of Hedge Fund Holders: 113

MercadoLibre, Inc. (NASDAQ:MELI) is one of the best aggressive growth stocks to buy according to Wall Street analysts. On May 8, Raymond James reduced its price target on MercadoLibre, Inc. (NASDAQ:MELI) from $2,250 to $2,000 while keeping a Strong Buy rating on the stock.

The research firm said the lower price target is based on reduced estimates and a valuation of 23 times the company’s expected 2028 earnings. Raymond James noted that this valuation is near the lower end of the company’s historical trading range.

According to Raymond James, the lower valuation also reflects a period of increased investment by MercadoLibre, Inc. (NASDAQ:MELI). The research firm said that it still sees an attractive risk and reward profile for the company because of its compounding network effects across its commerce, payments, logistics, and advertising businesses.

Raymond James also said that the market does not fully appreciate MercadoLibre, Inc.’s (NASDAQ:MELI) medium- to long-term profit margin potential.

MercadoLibre, Inc. (NASDAQ:MELI) is the leading e-commerce and financial technology company in Latin America with a presence in 18 countries.

1. Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)

Year-Over-Year Revenue Growth: 82.57%

Average Price Target Upside Potential According to Analysts: 56.05%

Number of Hedge Fund Holders: 67

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) is one of the best aggressive growth stocks to buy according to Wall Street analysts. On May 5, H.C. Wainwright reaffirmed its Buy rating on Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) with a price target of $510 on the stock. This update came after the company reported Q1 results.

The company reported total net product revenue of $1.036 billion for Q1 2026, up 121% year-over-year. H.C. Wainwright had estimated $1.071 billion. During the quarter, the company’s transthyretin (TTR) franchise brought in $910.4 million in revenue, an increase of 153% year-over-year. However, this also came in under H.C. Wainwright’s expectation of $929.1 million.

The research firm noted that Alnylam Pharmaceuticals, Inc.’s (NASDAQ:ALNY) drug AMVUTTRA is approaching parity with Pfizer’s VYNDAMAX in new patient starts for transthyretin amyloidosis with cardiomyopathy, based on the company’s own estimates.

The company kept its full-year 2026 total net product revenue guidance range between $4.90 billion to $5.30 billion. Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) also reiterated revenue guidance for the TTR franchise between $4.40 billion and $4.70 billion. At the midpoint, this implies 83% year-over-year growth.

As of March 31, Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) had $3.0 billion in cash. The company expects several upcoming catalysts this year, including updates from its ongoing Phase 3 ZENITH trial for zilebesiran.

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) is a global biopharmaceutical company that is widely known as the leader in RNA interference (RNAi) therapeutics. It focuses on developing transformative therapies with the potential to prevent, halt, or reverse rare and prevalent diseases.

READ NEXT: 10 Mid-Cap Stocks That Are On Fire Right Now and 10 Best US Stocks Under $5 to Buy.

Disclosure: None.